“What do we do about CMV?” Good luck getting universal agreement on the answer to THAT question! This little herpesvirus can cause BIG problems in certain susceptible transfusion recipients. Dr. John Roback has spent the last few years at the heart of the debate, and he’s here to help!
Shouldn’t This be Simple?
Both before and after publication of a landmark study by Bowden and colleagues in 1995 (see reference below), an argument has raged in the U.S. about whether at-risk patients require blood that is “CMV-seronegative” (meaning the donor has been tested for antibodies against CMV, and is negative), or whether, since CMV lives long-term in monocytes after infection, it is sufficient to “leukocyte reduce” the units to be transfused. Yet another group suggests it’s best to do BOTH CMV serologic testing AND leukocyte reduction (the so-called “belt and suspenders” approach). Thousands of pages have been written, voices have been raised, tears have been shed…you get the picture.
Dr. John Roback has been at the forefront of this “battle.” He was senior author on a 2016 AABB Committee Report (reference below) that was originally intended to end the argument. However, Dr. Roback and his colleagues on the AABB Clinical Transfusion Medicine Committee found the “evidence” to be…well, it wasn’t good! They decided instead to summarize the information to date, and John is here today to tell us all about it!
I have previously expressed my personal feelings on TT-CMV prevention, both on this podcast (see Episode 044, where I discuss it with Pat Kopko) and in a video I did on leukoreduction in 2013 (it’s a little dated now, but still relevant). In short, I don’t completely agree with Dr. Roback’s philosophy outlined in this interview, as I generally believe that modern prestorage leukocyte reduction really is equivalent to CMV testing, but this just illustrates again the variation in practice in the U.S.! Seriously, can’t we just get pathogen reduction figured out for all products so we can stop worrying about CMV??
Dr. John Roback is a graduate of the University of Chicago Pritzker School of Medicine for both his MD and PhD. He is a Professor of Pathology and Laboratory Medicine at Emory University in Atlanta, GA, where he is medical director of the Emory University Blood Bank and the Emory Medical Laboratories. He is also Director of the Emory Center for Transfusion and Cellular Therapy.
Dr. Roback, in addition to serving as editor-in-chief of the 16th and 17th editions of the AABB Technical Manual, has authored numerous peer-reviewed scientific articles and book chapters, including several on the TT-CMV issue discussed in this podcast. His research focuses primarily on improving the safety and efficacy of blood transfusion and hematopoietic stem cell transplantation. He received the prestigious “President’s Award” from AABB at the 2017 Annual Meeting.
This podcast episode offers a FREE continuing education activity where you can earn the following types of credit: 1 AMA PRA Category 1 CreditTM, 1 ASCLS P.A.C.E. ® Contact Hour (including Florida Clinical Laboratory Credit), and American Board of Pathology Self-Assessment Modules (SAMs) for Maintenance of Certification MOC).
To receive credit, review the accreditation information and related disclosures, please visit Transfusion News Continuing Education on Wiley Health Learning.
DISCLAIMER: The opinions expressed on this episode are those of my guest and I alone, and do not reflect those of the organizations with which either of us is affiliated. Neither Dr. Roback nor I have any relevant financial disclosures.
The images below are ©2013, Wiley Publishing (used with permission of Wiley Publishing and Dr. Roback). Please do not reproduce without permission from Wiley Publishing.
- AABB Committee Report on TT-CMV: AABB Clinical Transfusion Committee et al. AABB Committee Report: Reducing Transfusion-transmitted Cytomegalovirus Infections. Transfusion 2016;56:1581-1587.
- The classic “Bowden Study” on LR vs. CMV serology: Bowden RA et al. A Comparison of Filtered Leukocyte-Reduced and Cytomegalovirus (CMV) Seronegative Blood Products for the Prevention of Transfusion-Associated CMV Infection After Marrow Transplant. Blood 1995;86(9):3598-3603.
- Excellent editorial by Drs Roback and Josephson outlining new thoughts about TT-CMV prevention: Roback JD and Josephson CD. New insights for preventing transfusion-transmitted cytomegalovirus and other white blood cell–associated viral infections. Transfusion 2013;53:2112-2116.
- Article describing the “one-year CMV-positive” donor strategy: Ziemann M et al. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 2007;47:1972-1983.
- Article describing “window-period” TT-CMV: Ziemann M et al. Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections. Transfusion 2013;53:1088-1094.
- Article on effectiveness of LR for TT-CMV prevention: Thiele T et al. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation. Transfusion 2011;51:2620-2626.